Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2)

The persistence of immunogenicity in patients with immune-mediated inflammatory diseases (IMID) on disease-modifying antirheumatic therapy (DMARD) has been less well studied. This extension study evaluates the SARS-CoV2 antibody decay kinetics 6 months following two doses of ChAdO1nCov-19 (AZ) and B...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Ai Phuong, Tassone, D.F, Ding, N S, Nossent, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990163/
https://www.ncbi.nlm.nih.gov/pubmed/36863751
http://dx.doi.org/10.1136/rmdopen-2022-002871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990163/
https://www.ncbi.nlm.nih.gov/pubmed/36863751
http://dx.doi.org/10.1136/rmdopen-2022-002871

Ejemplares similares